Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 6, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/1756-8722-6-74
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81100353, 91129720, 81270604]
- Natural Science Foundation of Guangdong Province, China [S2013020012863]
- Guangdong Science & Technology Project [2012B050600023]
- Fundamental Research Funds for the Central Universities [21612116]
Ask authors/readers for more resources
T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. We are beginning to understand the power of co-inhibitors in the context of lymphocyte homeostasis and the pathogenesis of leukemia, which involves several newly described co-inhibitory pathways, including the programmed death-1 (PD-1) and PD-1 ligand (PD-L1) pathway. The aim of this review is to summarize the PD-1 and PD-L1 biological functions and their alterative expression in hematological malignancies. The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available